Core Insights - Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases [4] - The company has granted an inducement award to a new employee, consisting of an option to purchase 11,000 shares at an exercise price of $36.00 [1] - The option vests 25% on June 3, 2025, with the remainder vesting in three equal annual installments, fully vesting by June 3, 2028 [1] Company Overview - Cartesian Therapeutics is developing its lead asset, Descartes-08, which is in Phase 2b clinical development for generalized myasthenia gravis [4] - The company plans additional Phase 2 studies in systemic lupus erythematosus and basket trials for other autoimmune indications [4] - The clinical pipeline also includes Descartes-15, a next-generation autologous anti-BCMA mRNA CAR-T [4]

Cartesian Therapeutics, Inc. (RNAC) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead pipeline candidate, Descartes-08, for the treatment of myasthenia gravis ("MG"), an autoimmune disease associated with muscle weakness. Shares of the company were up 3.5% on May 22 following the announcement of the news. The RMAT designation is generally granted by the FDA to therapies that are intended to treat or cure a serious or life-threatening disease and hav ...

GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the U.S. Food and Drug Administration ("FDA") has granted Regenerative Medicine Advanced Therapy ("RMAT") designation for Descartes-08 for the treatment of myasthenia gravis ("MG"). Descartes-08, the Company's lead product candidate, is an autologous mRNA CAR-T directed against the B ...

Core Viewpoint - Cartesian Therapeutics has received RMAT designation from the FDA for its lead product candidate Descartes-08, aimed at treating myasthenia gravis, highlighting its potential as a first-in-class mRNA CAR-T therapy in the autoimmune disease treatment landscape [1][3]. Company Overview - Cartesian Therapeutics is a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, with Descartes-08 being its lead asset currently in Phase 2b clinical development for generalized myasthenia gravis [7]. Product Details - Descartes-08 is an autologous mRNA CAR-T therapy targeting the B cell maturation antigen (BCMA), specifically developed for myasthenia gravis, a chronic autoimmune disorder characterized by muscle weakness and fatigue [2][4]. - The therapy has previously received Orphan Drug Designation from the FDA for the treatment of myasthenia gravis [4]. Clinical Development - Positive twelve-month follow-up data from a Phase 2a study indicated that Descartes-08 was well-tolerated, showing durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores without dose-limiting toxicities [5]. - The company is on track to report topline data from its ongoing Phase 2b randomized, double-blind, placebo-controlled trial in mid-2024 [6]. Regulatory Designation - The RMAT designation allows for expedited development processes, including early and frequent interactions with the FDA, aimed at addressing unmet medical needs for serious conditions [3].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | ...

Exhibit 99.1 Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Topline data from Phase 2b trial of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024 On track to dose first patient in Phase 2 trial of Descartes-08 in SLE in 2Q24, as well as Phase 2 basket studies in additional autoimmune indications in 2H24 Dr. Brunn continued, "Additionally, we were excited to announce plans to transition to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: 001-37798 Cartesian Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (State or other jurisdi ...

Exhibit 99.1 Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR- T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024 On track to initiate Phase 2 study of Descartes-08 in systemic lupus erythematosus (SLE) in 1H24 as well as Phase 2 basket studies in additional autoimmune indications in 2H24 Following recent IND clearance, planning underway for first ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Cartesian Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (State ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (State or othe ...